翰森制药（03692）：收盘价潜在涨幅港元35.48港元44.50↓+25.4%

Investment Rating - The report maintains a "Buy" rating for the company, Hansoh Pharmaceutical (3692 HK), with a target price adjusted to HKD 44.50, indicating a potential upside of 25.4% from the current price of HKD 35.48 [1][6][10]. Core Insights - The company exceeded expectations in its 2025 performance, with innovative drugs contributing nearly 70% to product sales revenue. The collaboration income has also normalized, enhancing overall performance. The mid-to-late stage pipeline is rich and progressing rapidly, with a new wave of product launches expected starting in 2027, providing greater visibility for long-term growth [2][6]. - The company reported a year-on-year revenue growth of 23% and a net profit growth of 27% for 2025, reaching RMB 15.03 billion and RMB 5.56 billion, respectively. Product sales revenue increased by 20.8%, with innovative drug revenue rising by 30%, accounting for 68% of total sales [6][11]. - The report highlights the efficient advancement of the innovative pipeline, with several key products expected to enter critical phases in 2026. Notable products include HS-20093, HS-20089, HS-20094, and HS-10374, with multiple products set to initiate Phase III or key registration clinical trials this year [6][11]. Financial Performance - The company’s revenue forecast for 2026 is RMB 16.81 billion, with an EBIT of RMB 5.25 billion. The net profit for 2026 is projected to be RMB 5.02 billion, reflecting a slight decrease from 2025 due to increased R&D expenses [11][12]. - The report indicates a continuous increase in R&D investment, expected to rise by over 30% in 2026, with a focus on maintaining a robust pipeline and supporting future growth [6][11]. - The financial ratios indicate a healthy gross margin of approximately 89.7% for 2026, with a net profit margin of 29.9% [12].